Market capitalization | $1.68m |
Enterprise Value | $9.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 28.52 |
P/S ratio (TTM) P/S ratio | 5.09 |
P/B ratio (TTM) P/B ratio | 0.14 |
Revenue growth (TTM) Revenue growth | -65.22% |
Revenue (TTM) Revenue | $330.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Aditx Therapeutics Inc:
1 Analyst has issued a forecast Aditx Therapeutics Inc:
Jun '24 |
+/-
%
|
||
Revenue | 0.33 0.33 |
65%
65%
|
|
Gross Profit | -0.72 -0.72 |
89%
89%
|
|
EBITDA | -33 -33 |
47%
47%
|
EBIT (Operating Income) EBIT | -34 -34 |
45%
45%
|
Net Profit | -43 -43 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.
Head office | United States |
CEO | Amro Albanna |
Employees | 47 |
Founded | 2017 |
Website | www.aditxt.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.